Childhood-Onset Myasthenia Gravis Patients Benefited from Thymectomy in a Long-Term Follow-up Observation

Qing Zhang1, Yayun Cao2, Zhuajin Bi1, Xue Ma1, Mengge Yang1, Huajie Gao1, Mengcui Gui1, Bitao Bu1

1Department of Neurology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei Province, China
2Department of Radiology, Zhongnan Hospital, Wuhan University, Wuhan, Hubei Province, China

Address for correspondence Bitao Bu, MD, PhD, Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei Province, China (e-mail: bubitao@tjh.tjmu.edu.cn).

Abstract

Introduction  The effect of thymectomy on the treatment of childhood-onset myasthenia gravis (CMG) remains debatable. The objective of this study was to evaluate the clinical outcome and relevant prognostic factors of thymectomy for CMG patients.

Materials and Methods  A total of 32 CMG patients who underwent thymectomy before 18 years of age were included in this retrospective study. Clinical state following thymectomy was assessed by quantified myasthenia gravis (QMG) scores, myasthenia gravis–related activities of daily living (MG-ADL) scores, and Myasthenia Gravis Foundation of America postintervention status. Repeated-measures analysis of variance (ANOVA) examined the changes in postoperative scores during the 5-year follow-up. Univariate logistic regression was applied to identify factors associated with short-term (1-year postoperation) and long-term (5-year postoperation) clinical outcomes.

Results  Repeated-measures ANOVA showed that QMG scores ($F = 6.737, p < 0.001$) and MG-ADL scores ($F = 7.923, p < 0.001$) decreased gradually with time. Preoperative duration (odds ratio [OR] = 0.85, 95% confidence interval [CI]: 0.73–1.00, $p = 0.043$), gender (OR = 0.19, 95% CI: 0.04–0.94, $p = 0.041$), and MG subgroup (OR = 13.33, 95% CI: 1.43–123.99, $p = 0.023$) were predictors for 1-year postoperative prognosis. Shorter disease duration (OR = 0.82, 95% CI: 0.70–0.97, $p = 0.018$) and generalized CMG (OR = 6.11, 95% CI: 1.06–35.35, $p = 0.043$) were found to have more favorable long-term results.

Conclusion  Our results suggest that thymectomy is effective in treating CMG. Thymectomy could be recommended for CMG patients, especially for patients in the early course of CMG.
Introduction

Myasthenia gravis (MG) is an autoimmune disease caused by antibodies against postsynaptic membrane proteins at the neuromuscular junction.\(^1\) Childhood-onset myasthenia gravis (CMG), with MG signs and symptoms before 14 years of age, accounts for more than 50% of all MG patients in Asians.\(^2\) CMG cases present with higher frequency of ocular symptoms such as ptosis and ophthalomplegia, and often show a benign course of disease.\(^3\) The treatment modalities for CMG largely stem from adult regimens, but differences about the option for thymectomy exist between adult-onset myasthenia gravis (AMG) and CMG patients.\(^4\)

Thymic abnormalities could be the initial step to trigger the production of circulating antibodies and the impairment of neuromuscular transmission in MG.\(^5\) In CMG, thymomas can be detected in 10 to 15% of patients and thymic hyperplasia in 75 to 85% of patients.\(^3\) Multiple studies have confirmed a beneficial response to thymectomy in AMG patients with high remission rates.\(^6\) However, thymectomy during early childhood might increase future risk of autoimmunity or infection.\(^8\)

Although data regarding the efficacy on children are limited, thymectomy is a choice of treatments for refractory CMG.\(^9\) In this study, we have retrospectively analyzed the short-term and long-term postoperative follow-up data to clarify the efficacy and predictors of thymectomy in CMG.

Materials and Methods

Study Subjects

This is an observational retrospective study. Among 267 consecutive CMG patients admitted to the Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology from July 2003 to March 2020, 32 patients who underwent thymectomy were included in this study. Ethical approval was permitted by Tongji Hospital Ethics Committee and all patients provided written informed consent before enrollment.

The inclusion criteria were (1) MG diagnosis (fluctuating muscle weakness with one or more of the following criteria: [a] positive AChR-ab assay; [b] the presence of a 10% or greater decrement following repetitive nerve stimulation; and [c] positive response to pyridostigmine treatment), (2) onset age younger than 14 years, (3) underwent thymectomy before 18 years of age, and (4) at least 5 years of follow-up after operation. Patients with CMG have accepted thymectomy because medical therapy did not improve the systemic/bulbar/ocular symptoms or neoplasm of thymus detected by chest computed tomography/magnetic resonance imaging.

Classification Standards and Clinical Responses

Myasthenia Gravis Foundation of America (MGFA) clinical classification\(^10\) was used to evaluate the severity of the disease: class I (ocular MG [OMG]); classes II to IV (generalized MG [GMG]). Quantified MG (QMG) scores\(^10\) and MG-related activities of daily living (MG-ADL) scores\(^11\) were collected annually. Relapse of MG was defined as recurrent or clinical signs and symptoms necessitating reintroduction of acetylcholinesterase inhibitors.\(^12\)

The prognosis of the thymectomy for MG was defined according to MGFA Postintervention Status\(^13\) as: complete stable remission, pharmacological remission, minor manifestation, improvement, unchanged, worse, exacerbation, and death. Good outcome was defined as improvement or better status as previously described.\(^14\)

Statistical Analysis

Continuous variables were expressed as mean ± standard deviation or median with interquartile range (25–75%); categorical variables were expressed as numbers and percentages (%). We reported outcome measures according to the length of follow up: short-term (1-year postoperation) and long-term (5-year postoperation). Binary logistic regression was applied to determine the independent predictors for improvement or better status. Repeated-measures data were statistically analyzed using repeated-measures analysis of variance (ANOVA). All statistical analyses were performed with IBM SPSS 24.0 and GraphPad Prism 8.01. The p-values less than 0.05 for two-sided tests were considered statistically significant.

Results

Clinical Data of All Cases

There were 17 females (53.13%) and 15 males (46.87%), with a mean age at operation of 13.77 ± 3.35 years included in this study. The median time of preoperative duration was 5.80 (1.88–12.13) years. Nine patients (28.13%) experienced relapse and their median time to the first relapse was 2.80 (1.33–3.50) years after the operation. The detailed information on each patient is listed in -Table 1.

Efficacy of Thymectomy at Appointed Time Points

Proportions of improvement or better status after thymectomy were 65.63% in 1 year, 53.12% in 3 years, and 62.50% in 5 years (\(^1\) Fig. 1A). Repeated-measures ANOVA showed that QMG scores (\(F = 6.737, p < 0.001\)) and MG-ADL scores (\(F = 7.923, p < 0.001\)) decreased gradually over time (\(^1\) Fig. 1B).

At different time points, the short duration subgroup (< 6 years) showed more significant decreases in QMG scores (\(F = 2.885, p = 0.033\)) and MG-ADL scores (\(F = 3.638, p = 0.013\)) than the long duration subgroup (≥ 6 years).

Analyses of repeated measures also showed QMG scores (\(F = 17.343, p < 0.001\)) and MG-ADL scores (\(F = 13.283, p < 0.001\)) decreased significantly in the CMG subgroup compared with the OMG subgroup.

Short-Term and Long-Term Effects of Thymectomy in CMG

Effects of related variables on short-term and long-term outcomes are shown in -Table 2. Univariate analysis showed that preoperative duration (odds ratio [OR] = 0.85, 95% confidence interval [CI]: 0.73–1.00, \(p = 0.043\)), sex (males vs. females, OR = 0.19, 95% CI: 0.04–0.94, \(p = 0.041\)), and MG...
Table 1  Key clinical data from 32 patients with childhood-onset myasthenia gravis undergoing thymectomy

| S. no. | Sex | Age at onset, y | Preoperative duration, y | Preoperative MGFA classification | AChR-Ab | Thymus histology | Surgical approach | Postoperative treatment | Time to relapse, y | Outcome 1-y postoperation | Outcome 5-y postoperation |
|--------|-----|----------------|--------------------------|---------------------------------|---------|-----------------|---------------------|-----------------------|-----------------|--------------------------|--------------------------|
| 1      | M   | 5.00           | 4.00                     | I                               | –       | Hyperplasia     | Open                | Pyri + Pred           | N               | Unchanged               | Unchanged               |
| 2      | M   | 3.00           | 13.00                    | I                               | +       | Hyperplasia     | Open                | Pyri + Pred + TAC    | N               | Unchanged               | Unchanged               |
| 3      | F   | 7.00           | 7.00                     | I                               | +       | Thymolipoma     | Open                | Pyri + Pred + TAC    | N               | Unchanged               | Improvement            |
| 4      | F   | 2.00           | 5.00                     | Ia                              | +       | Hyperplasia     | VATS                | Pyri + Pred           | N               | Improvement             | Improvement            |
| 5      | F   | 2.00           | 15.75                    | I                               | –       | Hyperplasia     | VATS                | Pyri + Pred + TAC    | N               | Unchanged               | Unchanged               |
| 6      | M   | 8.42           | 1.00                     | Iib                             | +       | Hyperplasia     | Open                | Pyri + Pred + TAC    | 0.50 | Improvement             | Unchanged               |
| 7      | F   | 12.00          | 0.25                     | I                               | +       | Hyperplasia     | Open                | Pyri                | 4.00 | MM                      | MM                      |
| 8      | M   | 2.20           | 15.13                    | I                               | +       | Normal          | VATS                | Pyri + Pred + TAC    | N               | Unchanged               | Unchanged               |
| 9      | M   | 11.00          | 6.80                     | I                               | –       | Hyperplasia     | Open                | Pyri                | N               | MM                      | MM                      |
| 10     | F   | 14.00          | 3.84                     | I                               | –       | Hyperplasia     | VATS                | Pyri + Pred           | N               | Unchanged               | Unchanged               |
| 11     | F   | 2.00           | 5.70                     | Iib                             | +       | Hyperplasia     | VATS                | Pyri + Pred + TAC    | N               | Improvement             | MM                      |
| 12     | M   | 7.00           | 5.00                     | I                               | –       | Hyperplasia     | Open                | Pyri                | 3.00 | Unchanged               | Unchanged               |
| 13     | M   | 1.60           | 12.30                    | I                               | +       | Hyperplasia     | VATS                | Pyri + Pred + TAC    | N               | Unchanged               | Unchanged               |
| 14     | F   | 2.50           | 8.90                     | Ia                              | +       | Hyperplasia     | VATS                | Pyri + Pred + TAC    | 2.70 | Improvement             | MM                      |
| 15     | F   | 13.00          | 0.17                     | I                               | –       | B1 thymoma      | Open                | Pyri + Pred           | N               | MM                      | MM                      |
| 16     | F   | 2.70           | 11.00                    | Ia                              | +       | B2 thymoma      | Open                | Pyri + Pred + TAC    | 5.00 | Improvement             | Exacerbation           |
| 17     | F   | 6.00           | 8.00                     | I                               | +       | Hyperplasia     | Open                | Pyri + Pred           | N               | MM                      | CSR                     |
| 18     | F   | 6.00           | 11.60                    | I                               | +       | Hyperplasia     | VATS                | Pred                | 2.80/5.00 | CSR                  | Exacerbation           |
| 19     | M   | 13.00          | 1.20                     | Ia                              | +       | Thymolipoma     | VATS                | Pyri + Pred           | N               | MM                      | MM                      |
| 20     | F   | 2.18           | 14.00                    | I                               | +       | Hyperplasia     | VATS                | Pyri + Pred + AZA    | 3.00 | MM                      | MM                      |
| 21     | M   | 2.00           | 15.90                    | Iib                             | –       | Hyperplasia     | VATS                | Pyri + Pred + TAC    | N               | Unchanged               | Improvement            |
| 22     | M   | 11.00          | 0.25                     | I                               | +       | Hyperplasia     | Open                | Pyri + Pred           | N               | MM                      | MM                      |
| 23     | F   | 6.00           | 11.50                    | I                               | +       | B1 thymoma      | Open                | Pyri + Pred + TAC    | N               | MM                      | MM                      |
| 24     | F   | 10.50          | 3.00                     | Ia                              | +       | Hyperplasia     | VATS                | Pyri + Pred + TAC    | N               | Improvement             | MM                      |
| 25     | M   | 1.50           | 16.00                    | I                               | +       | A thymoma       | Open                | Pyri + Pred           | N               | Unchanged               | Unchanged               |
| 26     | M   | 3.25           | 5.90                     | Iia                             | +       | Hyperplasia     | Open                | Pyri + Pred + TAC    | N               | Improvement             | MM                      |
| 27     | F   | 13.50          | 0.75                     | Ilb                             | +       | Normal          | Open                | Pyri + Pred + TAC    | 1.75 | MM                      | MM                      |
| 28     | M   | 11.15          | 1.50                     | Ilb                             | –       | Hyperplasia     | Open                | Pyri + Pred + MMF    | N               | MM                      | MM                      |

(Continued)
subgroup (MG vs. OMG, OR = 13.33, 95% CI: 1.43–123.99, p = 0.023) were factors affecting the short-term results. Shorter disease duration (OR = 0.82, 95% CI: 0.70–0.97, p = 0.018) and GMG subgroup (OR = 6.11, 95% CI: 1.06–35.35, p = 0.043) were predictors associated with 5-year improvement or better status after thymectomy.

**Discussion**

Thymectomy has been generally accepted as an important option for treating AMG, but the efficacy remains unclear in the sequence of treatments for CMG. Here, our case series have suggested that thymectomy was effective for CMG patients and evaluated the factors affecting the short-term and long-term outcomes.

Thymectomy provided excellent clinical improvement for MG patients and this effect increased over time. In our study, QMG scores and MG-ADL scores markedly decreased over time, indicating that various symptoms of CMG patients were relieved after the operation. The disease status in MG patients can remain unstable last from months to years after thymectomy. Our results showed that about one-quarter of participants had a relapse within 5 years, which is consistent with the previous study. Therefore, long-term follow-up is required as there is a likelihood of relapse.

Furthermore, there is insufficient evidence to determine the optimum timing for thymectomy in children. Our data showed that a long preoperative duration in patients with CMG was related to the poor prognosis of thymectomy, so early surgical treatment is recommended. The association between the long duration and the poor prognosis is probably due to the prolonged and cumulative damage at the neuromuscular plate. Some studies reported females with MG benefit more from the thymectomy, whereas others found no significant sex difference. This present study indicated the short-term benefits rather than the long-term benefits of thymectomy in the female gender. Further study on understanding the relationship between sex and the effect of thymectomy on CMG is required.

Thoracotomy is a traditionally surgical approach for MG patients as thoracoscopy has been widely performed. Kim et al concluded that thoracoscopic thymectomy is an effective treatment choice for juvenile MG and can be safely applied to children as young as 20 months of age. The minimally invasive approach is not superior to open thymectomy in disease control because thoracoscopy may be insufficient to remove all thymic tissue. Based on the results of our research, both thoracoscopy and thoracotomy had similar short-term and long-term prognoses for CMG patients.

This study demonstrated that thymectomy had a positive effect on short-term and long-term neurologic outcomes in generalized CMG. It was found that thymectomy is an effective therapy for children with systemic symptoms. Some experts suggested that thymectomy can improve the remission rate of ocular CMG, while others took the opposite attitude. The results in our research showed that thymectomy is more effective in generalized CMG patients and it is still an option for ocular patients with the decreases in their...
QMG scores \( (p < 0.05; \textit{-Fig. 2C}) \) and MG-ADL scores \( (p < 0.05; \textit{-Fig. 2F}) \) over time.

Immunomodulators are often accepted by MG patients during the postthymectomy period, which can help stabilize the illness and improve the prognosis for patients.\(^{35}\) A previous study by Liu et al demonstrated that tacrolimus can produce a favorable outcome in children with refractory MG.\(^{36}\) In this study, 14 CMG patients were treated with prednisone in combination with tacrolimus postoperatively, but we did not find a predictive value of the combined immunotherapy for the prognosis. The different results were most likely due to the need to use tacrolimus to control symptoms in our patients with poor clinical conditions.

There are some limitations to this study. First, our analysis was based on a single-center retrospective study and lacked randomization. Second, the sample size was relatively small and, therefore, we did not conduct the multivariate regression analysis. Third, due to the large time span, therapeutic patterns and attitudes of physicians have changed with the accumulation of experience. Further studies comprising greater numbers of subjects from multicenter are required to evaluate the clinical heterogeneity in patients with CMG following thymectomy.

**Conclusion**

In summary, our case series have suggested that thymectomy is an effective treatment for CMG. QMG scores and MG-ADL scores...
scores decreased gradually during the follow-up of 5 years. Patients with shorter course and generalized symptoms tended to have more favorable long-term outcomes. Therefore, thymectomy could be recommended for CMG patients, especially for patients in the early course of GMG.

**Funding**
This work was supported by a grant from the National Natural Science Foundation of China (No. 81873758).

**Conflict of Interest**
None declared.

**References**
1. Andrews PI. Autoimmune myasthenia gravis in childhood. Semin Neurol 2004;24(01):101–110
2. Huang X, Liu WB, Men LN, et al. Clinical features of myasthenia gravis in southern China: a retrospective review of 2,154 cases over 22 years. Neurol Sci 2013;34(06):911–917
3 Gui M, Luo X, Lin J, et al. Long-term outcome of 424 childhood-onset myasthenia gravis patients. J Neurol 2015;262(04):823–830
4 Madenci AL, Li GZ, Weil BR, Zurakowski D, Kang PB, Weldon CB. The role of thymectomy in the treatment of juvenile myasthenia gravis: a systematic review. Pediatr Surg Int 2017;33(06):683–694
5 Marx A, Porubsky S, Belharazem D, et al. Thymoma related myasthenia gravis in humans and potential animal models. Exp Neurol 2015;270:55–65
6 Raica M, Cimpean AM, Ribatti D. Myasthenia gravis and the thymus gland. A historical review. Clin Exp Med 2008;8(02):61–64
7 Kaufman AJ, Palatt J, Sivak M, et al. Thymectomy for myasthenia gravis: complete stable remission and associated prognostic factors in over 1000 cases. Semin Thorac Cardiovasc Surg 2016;28(02):561–568
8 Deya-Martinez A, Flinn AM, Genenny AR. Neonatal thymectomy in children-accelerating the immunologic clock? J Allergy Clin Immunol 2020;146(02):236–243
9 Essa M, El-Medany Y, Hajjar W, et al. Maximal thymectomy in children with myasthenia gravis. Eur J Cardiothorac Surg 2003;24(02):187–189, discussion 190–191
10 Jarettzki A III, Barohn RJ, Ernstoff RM, et al; Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Myasthenia gravis: recommendations for clinical research standards. Neurology 2000;55(01):16–23
11 Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology 1999;52(07):1487–1489
12 Gupta A, Goyal V, Srivastava AK, Shukla G, Behari M. Remission and relapse of myasthenia gravis on long-term azathioprine: an ambispective study. Muscle Nerve 2016;54(03):405–412
13 Gajdos P, Sharshar T, Chevret S. Standards of measurements in myasthenia gravis. Ann N Y Acad Sci 2003;988:445–452
14 Nikolic A, Djukic P, Rasta I, et al. The predictive value of the presence of different antibodies and thymus pathology to the clinical outcome in patients with generalized myasthenia gravis. Clin Neurol Neurosci 2013;115(04):432–437
15 Evoli A, Meacci E. An update on thymectomy in myasthenia gravis. Expert Rev Neurother 2019;19(09):823–833
16 Sonett JR, Magee MJ, Gorenstein L. Thymectomy and myasthenia gravis: a history of surgical passion and scientific excellence. J Thorac Cardiovasc Surg 2017;154(01):306–309
17 Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology 2016;87(04):419–425
18 Stern LE, Nussbaum MS, Quinlan JC, Fischer JE. Long-term evaluation of extended thymectomy with anterior mediastinal dissection for myasthenia gravis. Surgery 2001;130(04):774–778, discussion 778–780
19 Endo S, Yamaguchi T, Saito N, et al. Experience with programmed steroid treatment with thymectomy in nonthymomatous myasthenia gravis. Ann Thorac Surg 2004;77(05):1745–1750
20 Nakamura H, Taniguchi Y, Suzuki Y, et al. Delayed remission after thymectomy for myasthenia gravis of the purely ocular type. J Thorac Cardiovasc Surg 1996;112(02):371–375
21 Hsu HS, Huang CS, Huang BS, et al. Thymoma is associated with relapse of symptoms after transternal thymectomy for myasthenia gravis. Interact Cardiovasc Thorac Surg 2006;5(01):42–46
22 Heng HS, Lim M, Absoud M, et al. Outcome of children with acetylcholine receptor (AChR) antibody positive juvenile myasthenia gravis following thymectomy. Neuromuscul Disord 2014;24(01):25–30
23 Liu C, Liu P, Zhang XJ, Li WQ, Qi G. Assessment of the risks of a myasthenic crisis after thymectomy in patients with myasthenia gravis: a systematic review and meta-analysis of 25 studies. J Cardiothorac Surg 2020;15(01):270
24 Téllez-Zenteno JF, Remes-Troche JM, García-Ramos G, Estañol B, Garduño-Espinoza J. Prognostic factors of thymectomy in patients with myasthenia gravis: a cohort of 132 patients. Eur Neurol 2001;46(04):171–177
25 Al-Bulushi A, Al Salmi I, Al Rahbi F, Farsi AA, Hannawi S. The role of thymectomy in myasthenia gravis: a programmatic approach to thymectomy and perioperative management of myasthenia gravis. Asian J Surg 2021;44(06):819–828
26 Lee I, Kaminski HJ, Xin H, Cutter G. Gender and quality of life in myasthenia gravis patients from the Myasthenia Gravis Foundation of America Registry. Muscle Nerve 2018
27 Huang CS, Hsu HS, Huang BS, et al. Factors influencing the outcome of transternal thymectomy for myasthenia gravis. Acta Neurol Scand 2005;112(02):108–114
28 Nieto IP, Robledo JP, Pajuelo MC, et al. Prognostic factors for myasthenia gravis treated by thymectomy: review of 61 cases. Ann Thorac Surg 1999;67(06):1568–1571
29 Derderian SC, Potter DD, Bansal S, Rowe PG, Partrick DA. Open versus thoracoscopic thymectomy for juvenile myasthenia gravis. J Pediatr Surg 2020;55(09):1850–1853
30 Kim AG, Upah SA, Brandsem JF, Yum SW, Blinman TA. Thoracoscopic thymectomy for juvenile myasthenia gravis. Pediatr Surg Int 2019;35(05):603–610
31 Goldstein SD, Culbertson NT, Garrett D, et al. Thymectomy for myasthenia gravis in children: a comparison of open and thoracoscopic approaches. J Pediatr Surg 2015;50(01):92–97
32 Liew WK, Kang PB. Update on juvenile myasthenia gravis. Curr Opin Pediatr 2013;25(06):694–700
33 Castro D, Derisavifard S, Anderson M, Greene M, lannaccone S. Juvenile myasthenia gravis: a twenty-year experience. J Clin Neuromuscul Dis 2013;14(03):95–102
34 Liu Z, Feng H, Yeung SC, et al. Extended transternal thymectomy for the treatment of ocular myasthenia gravis. Ann Thorac Surg 2011;92(06):1993–1999
35 Porset JM, Gamez J, Azem J, et al. Post-thymectomy combined treatment of prednisone and tacrolimus versus prednisone alone for consolidation of complete stable remission in patients with myasthenia gravis: a non-randomized, non-controlled study. Curr Med Res Opin 2007;23(06):1269–1278
36 Liu C, Gui M, Cao Y, et al. Tacrolimus improves symptoms of children with myasthenia gravis refractory to prednisone. Pediatr Neurol 2017;77:42–47